Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL CHRISTOPHER JOYCE

Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology

NPI
1700045713
CMS profile
77679
Location
SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$79,055.13

79 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $58,347.85 35
ABBVIE INC. $15,223.95 20
Regeneron Healthcare Solutions, Inc. $2,793.83 14
PFIZER INC. $2,569.82 9
Lilly USA, LLC $119.68 1

Page 1 of 2; records 1–50 of 79 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL CHRISTOPHER JOYCE

NPI 1700045713 · CMS profile ID 77679

Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology

SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 79 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700045713?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 79 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700045713?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 79 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700045713?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 79 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1700045713?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

79 matching records · $79,055.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 79 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 79.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $119.6812/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135027056 CMS
PFIZER INC. $20.3712/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131071674 CMS
ABBVIE INC. $20.0012/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190446 CMS
ABBVIE INC. $2,875.0012/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103156856 CMS
GENZYME CORPORATION $11.6511/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574357 CMS
GENZYME CORPORATION $14.2011/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574355 CMS
PFIZER INC. $2.6311/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131178240 CMS
Regeneron Healthcare Solutions, Inc. $36.1211/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114080077 CMS
ABBVIE INC. $2,875.0011/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103156854 CMS
ABBVIE INC. $20.0011/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190444 CMS
ABBVIE INC. $123.4411/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104014642 CMS
ABBVIE INC. $12.2811/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104014638 CMS
ABBVIE INC. $34.6511/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104014640 CMS
ABBVIE INC. $481.5011/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190442 CMS
GENZYME CORPORATION $500.0010/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574367 CMS
GENZYME CORPORATION $250.0010/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574369 CMS
GENZYME CORPORATION $500.0010/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574371 CMS
GENZYME CORPORATION $12,024.0010/22/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1155226104 CMS
GENZYME CORPORATION $31.6310/22/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155226106 CMS
GENZYME CORPORATION $74.8610/22/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155226108 CMS
GENZYME CORPORATION $200.3210/22/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155226110 CMS
GENZYME CORPORATION $10,008.0010/22/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155226112 CMS
GENZYME CORPORATION $57.9910/22/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155226114 CMS
ABBVIE INC. $3.7110/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104014634 CMS
ABBVIE INC. $85.8310/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104014636 CMS
ABBVIE INC. $505.5810/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190440 CMS
GENZYME CORPORATION $4,697.0010/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574343 CMS
GENZYME CORPORATION $464.6410/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574345 CMS
Regeneron Healthcare Solutions, Inc. $38.9310/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114080075 CMS
PFIZER INC. $15.7309/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131938745 CMS
Regeneron Healthcare Solutions, Inc. $2,135.0009/20/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114080073 CMS
ABBVIE INC. $2,875.0007/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103156852 CMS
GENZYME CORPORATION $78.8707/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574321 CMS
GENZYME CORPORATION $4,697.0007/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574323 CMS
GENZYME CORPORATION $489.1007/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574325 CMS
Regeneron Healthcare Solutions, Inc. $31.4107/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114080067 CMS
Regeneron Healthcare Solutions, Inc. $4.5707/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114080069 CMS
Regeneron Healthcare Solutions, Inc. $50.1307/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114080071 CMS
GENZYME CORPORATION $29.4307/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574291 CMS
GENZYME CORPORATION $80.3607/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574293 CMS
PFIZER INC. $2,520.0007/01/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131722822 CMS
ABBVIE INC. $112.9206/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104014632 CMS
ABBVIE INC. $505.5806/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190438 CMS
ABBVIE INC. $6.9506/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104014630 CMS
ABBVIE INC. $2,875.0006/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103156850 CMS
PFIZER INC. $1.1505/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131649554 CMS
GENZYME CORPORATION $106.6705/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574303 CMS
GENZYME CORPORATION $4,270.0005/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574305 CMS
GENZYME CORPORATION $292.5405/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574307 CMS
GENZYME CORPORATION $52.0005/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139574309 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $700.40 2
PY2020 $2,376.00 1
PY2021 $2,246.65 3
PY2022 $2,632.70 9
PY2023 $23,671.61 40
PY2024 $79,055.13 79
PY2025 $92,566.63 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,750.00 4
PY2025 Principal investigator $694,810.55 184
PY2024 Recipient $7,148.03 20
PY2024 Principal investigator $657,792.45 167
PY2023 Recipient $3,281.97 14
PY2023 Principal investigator $421,779.06 92
PY2022 Recipient $1,517.38 3
PY2022 Principal investigator $234,287.76 66
PY2021 Principal investigator $111,180.61 56
PY2020 Principal investigator $343,493.78 70
PY2019 Principal investigator $4,975.53 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

187 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $8,734.60 12/23/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128717373
Principal investigator 1 Incyte Corporation $1,062.40 12/20/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671745
Principal investigator 1 Incyte Corporation $3,751.00 12/20/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671747
Principal investigator 1 Incyte Corporation $4,229.00 12/20/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671755
Principal investigator 1 Incyte Corporation $4,229.00 12/20/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671785
Principal investigator 1 Galderma Laboratories, L.P. $2,346.32 12/19/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047933
Principal investigator 1 SANOFI US SERVICES INC. $897.35 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717375
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717377
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717379
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717381
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717383
Principal investigator 1 SANOFI US SERVICES INC. $897.35 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717385
Principal investigator 1 SANOFI US SERVICES INC. $897.35 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717387
Principal investigator 1 SANOFI US SERVICES INC. $897.35 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717389
Principal investigator 1 SANOFI US SERVICES INC. $897.35 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717391
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717393
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717395
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717397
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717399
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/17/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717401
Principal investigator 1 Janssen Research & Development, LLC $5,341.91 12/12/2024 Non-covered Recipient Entity
Endeavor Hlth
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962267
Principal investigator 1 Incyte Corporation $1,000.00 12/05/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671789
Principal investigator 1 Incyte Corporation $48.50 12/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671739
Principal investigator 1 Incyte Corporation $103.00 12/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671801
Principal investigator 1 Galderma Laboratories, L.P. $817.50 11/27/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047931
Principal investigator 1 SANOFI US SERVICES INC. $4,797.90 11/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128717371
Principal investigator 1 Incyte Corporation $10,696.10 11/21/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671777
Principal investigator 1 Galderma Laboratories, L.P. $3,391.76 11/14/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047929
Principal investigator 1 Incyte Corporation $2,662.00 11/13/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671749
Principal investigator 1 Incyte Corporation $706.20 11/13/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671751
Principal investigator 1 Incyte Corporation $2,573.00 11/13/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671753
Principal investigator 1 Incyte Corporation $3,751.00 11/13/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671787
Principal investigator 1 Incyte Corporation $4,229.00 11/13/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671805
Principal investigator 1 Janssen Research & Development, LLC $5,341.91 11/12/2024 Non-covered Recipient Entity
Endeavor Hlth
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962273
Principal investigator 1 ABBVIE INC. $1,881.48 11/06/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100688409
Principal investigator 1 Incyte Corporation $32.40 11/04/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671791
Principal investigator 1 SANOFI US SERVICES INC. $3,743.30 10/28/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128717367
Principal investigator 1 Galderma Laboratories, L.P. $2,346.32 10/24/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047927
Principal investigator 1 Janssen Research & Development, LLC $8,268.92 10/07/2024 Non-covered Recipient Entity
Northshore Univ Hlth System-Evanston Hosp
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962417
Principal investigator 1 Galderma Laboratories, L.P. $369.00 10/04/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047925
Principal investigator 1 Incyte Corporation $133.20 10/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671737
Principal investigator 1 Incyte Corporation $61.20 10/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671741
Principal investigator 1 Incyte Corporation $97.10 10/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671743
Principal investigator 1 Incyte Corporation $91.60 10/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671795
Recipient Regeneron Pharmaceuticals, Inc. $1,434.00 10/01/2024 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1082395134
Principal investigator 1 Galderma Laboratories, L.P. $5,308.02 09/26/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047923
Principal investigator 1 Janssen Research & Development, LLC $1,573.64 09/18/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962307
Principal investigator 1 SANOFI US SERVICES INC. $6,145.00 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128717291
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717293
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717295
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717297
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717299
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717301
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717303
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717305
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717307
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717309
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717311
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717313
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717315
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717317
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717319
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717321
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717323
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717325
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717327
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717329
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717331
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717333
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717335
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717337
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717339
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717341
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717343
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717345
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717347
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717349
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717351
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717353
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717355
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717357
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717359
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717361
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717363
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717365
Principal investigator 1 Incyte Corporation $2,750.00 09/12/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671783
Principal investigator 1 SANOFI US SERVICES INC. $500.00 09/04/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128717287
Principal investigator 1 Janssen Research & Development, LLC $6,494.92 08/30/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962309
Principal investigator 1 Incyte Corporation $1,314.90 08/29/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671781
Principal investigator 1 SANOFI US SERVICES INC. $10,636.00 08/26/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128717289
Principal investigator 1 Incyte Corporation $3,806.10 08/21/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671793
Principal investigator 1 PFIZER INC. $750.00 08/06/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131033553
Principal investigator 1 SANOFI US SERVICES INC. $18,221.00 08/05/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128717285
Principal investigator 1 Galderma Laboratories, L.P. $62.50 08/02/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047919
Principal investigator 1 Galderma Laboratories, L.P. $62.50 08/02/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047921
Principal investigator 1 ABBVIE INC. $197.30 08/01/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100688399
Principal investigator 1 Galderma Laboratories, L.P. $3,490.36 07/25/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047917
Principal investigator 1 Janssen Research & Development, LLC $3,347.64 07/22/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962285
Principal investigator 1 Incyte Corporation $82.00 07/18/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671775
Principal investigator 1 Incyte Corporation $3,208.38 07/11/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134671761
Principal investigator 1 Eli Lilly and Company $1,259.00 07/05/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1137349745
Principal investigator 1 Galderma Laboratories, L.P. $539.50 07/05/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047915
Principal investigator 1 ABBVIE INC. $3,860.16 07/03/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100688393
Principal investigator 1 Incyte Corporation $2,000.00 07/03/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671729
Principal investigator 1 Incyte Corporation $2,500.00 07/03/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671731
Principal investigator 1 Incyte Corporation $13,700.00 07/03/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671733
Principal investigator 1 Incyte Corporation $1,000.00 07/03/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1134671735
Principal investigator 1 Janssen Research & Development, LLC $8,604.82 07/01/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962317
Recipient Regeneron Pharmaceuticals, Inc. $431.22 07/01/2024 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1082395132
Principal investigator 1 Galderma Laboratories, L.P. $18,224.20 06/26/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047913
Principal investigator 1 Amgen Inc. $26,420.00 06/25/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309549
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717263
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717265
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717267
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717269
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717271
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717273
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717275
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717277
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717279
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717281
Principal investigator 1 Galderma Laboratories, L.P. $669.50 06/20/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047911
Recipient GENZYME CORPORATION $250.00 06/08/2024 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128705459
Recipient GENZYME CORPORATION $500.00 06/07/2024 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128705461
Principal investigator 1 PFIZER INC. $2,480.40 06/04/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131069552
Recipient Regeneron Pharmaceuticals, Inc. $416.67 06/01/2024 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1082395128
Recipient Regeneron Pharmaceuticals, Inc. $1,135.00 06/01/2024 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1082395130
Principal investigator 1 Incyte Corporation $5,504.40 05/30/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671773
Recipient GENZYME CORPORATION $500.00 05/24/2024 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128705467
Principal investigator 1 Incyte Corporation $124.00 05/16/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134671759
Recipient SANOFI US SERVICES INC. $234.91 05/16/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705441
Principal investigator 1 Janssen Research & Development, LLC $8,604.82 05/10/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962243
Principal investigator 1 PFIZER INC. $1,240.20 05/03/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131081727
Recipient SANOFI US SERVICES INC. $50.21 04/27/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705433
Recipient SANOFI US SERVICES INC. $247.28 04/27/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705443
Recipient SANOFI US SERVICES INC. $415.91 04/27/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705445
Recipient SANOFI US SERVICES INC. $517.54 04/27/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705447
Recipient SANOFI US SERVICES INC. $25.00 04/27/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705453
Recipient SANOFI US SERVICES INC. $50.21 04/26/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705431
Recipient SANOFI US SERVICES INC. $75.08 04/26/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705435
Recipient SANOFI US SERVICES INC. $167.60 04/26/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705439
Recipient SANOFI US SERVICES INC. $25.00 04/26/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705449
Recipient SANOFI US SERVICES INC. $25.00 04/26/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705451
Principal investigator 1 Incyte Corporation $41.00 04/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671771
Recipient SANOFI US SERVICES INC. $147.40 04/25/2024 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128705437
Principal investigator 1 Amgen Inc. $13,613.33 04/23/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309551
Principal investigator 1 Amgen Inc. $53,763.49 04/19/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
ASTRO P3 AD Adolescent Mono No dispute reported 06/30/2026 1096309923
Principal investigator 1 Amgen Inc. $27,661.30 04/19/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
Ph3 Otezla in Peds mild/mod PsO PMR No dispute reported 06/30/2026 1096314989
Principal investigator 1 Amgen Inc. $18,418.00 04/19/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
SHUTTLE P3 AD Adult Combo TCS No dispute reported 06/30/2026 1096315939
Principal investigator 1 Janssen Research & Development, LLC $2,300.64 04/19/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962303
Principal investigator 1 Incyte Corporation $4,429.80 04/11/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671769
Principal investigator 1 PFIZER INC. $3,720.60 04/05/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131088081
Principal investigator 1 ABBVIE INC. $2,391.68 04/04/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100688391
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717249
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717251
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717253
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717255
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717257
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717259
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/02/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128717261
Principal investigator 1 Janssen Research & Development, LLC $9,235.56 03/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962287
Principal investigator 1 Janssen Research & Development, LLC $233.00 03/15/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962233
Principal investigator 1 Eli Lilly and Company $23,391.24 03/07/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1137349747
Principal investigator 1 Incyte Corporation $7,776.00 03/07/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671767
Principal investigator 1 Incyte Corporation $2,264.73 03/06/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134671779
Recipient GENZYME CORPORATION $500.00 02/09/2024 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1128705425
Principal investigator 1 Amgen Inc. $132,873.31 02/01/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
Ph3 Otezla in Peds mild/mod PsO PMR No dispute reported 06/30/2026 1096314991
Principal investigator 1 Incyte Corporation $327.36 02/01/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134671757
Principal investigator 1 Janssen Research & Development, LLC $1,699.00 01/31/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962235
Principal investigator 1 Janssen Research & Development, LLC $3,267.28 01/31/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962271
Principal investigator 1 Galderma Laboratories, L.P. $647.50 01/29/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047909
Principal investigator 1 Incyte Corporation $82.00 01/29/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671763
Principal investigator 1 Incyte Corporation $41.00 01/29/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671765
Principal investigator 1 Incyte Corporation $41.00 01/29/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1134671799
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,588.74 01/26/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis No dispute reported 06/30/2026 1123473447
Principal investigator 1 Incyte Corporation $9,055.15 01/26/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134671803
Principal investigator 1 Galderma Laboratories, L.P. $8,372.98 01/25/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047901
Principal investigator 1 Galderma Laboratories, L.P. $409.00 01/25/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047903
Principal investigator 1 Galderma Laboratories, L.P. $852.00 01/25/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047905
Principal investigator 1 Galderma Laboratories, L.P. $471.20 01/25/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156047907
Principal investigator 1 Janssen Research & Development, LLC $3,787.64 01/25/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962299
Principal investigator 1 Amgen Inc. $13,910.26 01/22/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
ASTRO P3 AD Adolescent Mono No dispute reported 06/30/2026 1096309925
Principal investigator 1 Incyte Corporation $409.20 01/12/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134671797
Principal investigator 1 ABBVIE INC. $1,815.78 01/10/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100688383
Principal investigator 1 Janssen Research & Development, LLC $9,202.56 01/09/2024 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 1078962247
Principal investigator 1 Amgen Inc. $4,113.94 01/08/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
SHUTTLE P3 AD Adult Combo TCS No dispute reported 06/30/2026 1096315941
Principal investigator 1 PFIZER INC. $2,210.00 01/04/2024 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131093177